Sector
PharmaceuticalsOpen
₹2,280.95Prev. Close
₹2,256.55Turnover(Lac.)
₹81.41Day's High
₹2,292.2Day's Low
₹2,22252 Week's High
₹2,974.9552 Week's Low
₹1,381Book Value
₹266.49Face Value
₹8Mkt Cap (₹ Cr.)
3,787.68P/E
39.05EPS
57.77Divi. Yield
0.71Here are some of the stocks that may see significant price movement today: Adani Power & Adani Green, Hindustan Unilever, Dixon Technologies, etc.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 13.23 | 13.23 | 13.23 | 13.23 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 361.62 | 294.37 | 242.54 | 203.22 |
Net Worth | 374.85 | 307.6 | 255.77 | 216.45 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 440.16 | 389.14 | 375.57 | 343.95 |
yoy growth (%) | 13.11 | 3.61 | 9.19 | 17.13 |
Raw materials | -141.82 | -131.1 | -127.76 | -114.61 |
As % of sales | 32.22 | 33.68 | 34.01 | 33.32 |
Employee costs | -99.97 | -94.66 | -95.9 | -90.14 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 73.17 | 53.58 | 41.77 | 20.36 |
Depreciation | -15.66 | -16.47 | -16.36 | -14.34 |
Tax paid | -21.69 | -13.58 | -7.44 | -6.91 |
Working capital | 30 | 44.05 | -12.51 | 19.51 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 13.11 | 3.61 | 9.19 | 17.13 |
Op profit growth | 23.49 | 18.22 | 57.64 | 35.1 |
EBIT growth | 35.53 | 24.93 | 80.13 | 41.53 |
Net profit growth | 28.7 | 37.88 | 115.68 | -35.98 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,698.35 | 129.24 | 4,07,155.15 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,549.7 | 71.05 | 1,47,295.24 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,444.25 | 25.07 | 1,16,664.33 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183.9 | 59.03 | 1,07,673.27 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,458.1 | 52.42 | 1,01,358.17 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
H V Goenka
Company Sec. & Compli. Officer
Rajesh Shirambekar
Independent Director
Sachin Nandgaonkar
Independent Director
Zahabiya Khorakiwala
Managing Director
Yugal Sikri
Independent Director
Bhaskar Vemban Iyer
Non Executive Director
Rajat Bhargava
Independent Director
Hiten Kotak
Independent Director
Anil Matai
Independent Director
RADHIKA GUPTA
Additional Director
M K Maheshwari
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by RPG Life Sciences Ltd
Summary
RPG Life Sciences Limited, formerly Searle India Limited, started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to RPG Group. The Company is engaged in manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).RPG Life Sciences Limited was incorporated on March 29, 2007 with the name RPG Pharmaceuticals Limited . During the year 2007-08, as per the Scheme of Arrangement, the Company acquired the Pharmaceuticals Business of Brabourne Enterprises Limited along with all assets and liabilities pertaining to that business with effect from April 2, 2007. On February 13, 2008, the name of the Company was subsequently changed to RPG Life Sciences Limited.During the year 2008-09, the company increased the production capacity of Bulk Drugs and Chemicals from 62 tonnes to 71 tonnes. They launched an oncology drug namely Exemestane. Also, they launched new products, namely Nufex Beta, Qugyl-O & Immunotec. In June 10, 2008, the equity shares of the company were listed on BSE and NSE with effect from June 10, 2008. In July 2008, the company commenced production in the new high capacity fermenters. During the year 2009-10, the company strengthened their product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. The new products launched during the year were Demator, Sizomax, Mela,
Read More
The RPG Life Sciences Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹2290.15 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of RPG Life Sciences Ltd is ₹3787.68 Cr. as of 02 Apr ‘25
The PE and PB ratios of RPG Life Sciences Ltd is 39.05 and 9.83 as of 02 Apr ‘25
The 52-week high/low is the highest and lowest price at which a RPG Life Sciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of RPG Life Sciences Ltd is ₹1381 and ₹2974.95 as of 02 Apr ‘25
RPG Life Sciences Ltd's CAGR for 5 Years at 67.29%, 3 Years at 56.74%, 1 Year at 46.23%, 6 Month at -9.78%, 3 Month at 2.73% and 1 Month at 12.13%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.